Retrospective studies suggest that precipitating events such as prolonged seizures, stroke, or head trauma increase the risk of developing epilepsy later in life. The process of epilepsy development, known as epileptogenesis, is associated with changes in the expression of a myriad of genes. One of the major challenges for the epilepsy research community has been to determine which of these changes contributes to epileptogenesis, which may be compensatory, and which may be noncontributory. Establishing this for any given gene is essential if it is to be considered a therapeutic target for the prevention or treatment of epilepsy. Our laboratories have examined alterations in gene expression related to inhibitory neurotransmission that have been proposed as contributing factors in epileptogenesis. The GABA A receptor mediates most fast synaptic inhibition, and changes in GABA A receptor subunit expression and function have been reported in adult animals beginning immediately after prolonged seizures (status epilepticus [SE]) and continue as animals become chronically epileptic. Prevention of GABA A receptor subunit changes after SE using viral gene transfer inhibits development of epilepsy in an animal model, suggesting that these changes directly contribute to epileptogenesis. The mechanisms that regulate differential expression of GABA A receptor subunits in hippocampus after SE have recently been identified, and include the CREB-ICER, JAK-STAT, BDNF, and Egr3 signaling pathways. Targeting signaling pathways that alter the expression of genes involved in epileptogenesis may provide novel therapeutic approaches for preventing or inhibiting the development of epilepsy after a precipitating insult.
INTRODUCTION
It is clear from the results of research using various animal models and from human retrospective studies that an initial precipitating event such as status epilepticus (SE) can increase the risk of later epilepsy development (epileptogenesis). The process of epileptogenesis is likely to be complex and multifactorial. Determining whether changes in gene regulation that accompany the epileptic condition are consequential to or causative of disease etiology is the major difficulty of research in this area. Many laboratories, including our own, have focused on the role of gene regulation in determining changes in GABA receptor plasticity that occur during the latent period after brain insult and prior to the development of the epileptic state. GABA is the major inhibitory neurotransmitter in the mature brain, and various drugs that enhance GABAergic inhibition are commonly used as antiepileptic drugs. Also, drugs that block GABAergic inhibition can induce seizures in animals, further supporting the potential importance of alterations in GABAergic transmission in epileptogenesis.
ROLE OF GABA A RECEPTORS IN EPILEPSY
Three types of GABA receptors are found in the mature central nervous system: GABA A , GABA B , and GABA C . Both GABA A and GABA C are ionotropic receptors; GABA B is a metabotropic receptor. Most fast synaptic inhibition in the mature brain is mediated by GABA A receptors, whereas slow inhibition is mediated by GABA B receptors. GABA A receptors are composed of multiple subunit subtypes (␣1-6, ␤1-3, ␥1-3, ␦, , , , and 1-3) that form a pentameric anion-selective channel. 1, 2 The most common in vivo subunit composition is two ␣, two ␤, and one ␥ subunit. There is remarkable receptor heterogeneity, with subtype combinations varying in different brain regions and cell types, and during different times in ontogeny. [3] [4] [5] [6] Different subunit subtypes confer distinct functional and pharmacological properties to the receptors.
Prolonged seizures (i.e., SE) result in alterations in the expression and membrane localization of several GABA A receptor subunits (␣1, ␣4, ␥2, and ␦) in hippocampal dentate granule neurons. [7] [8] [9] These alterations, which are associated with changes in phasic and tonic GABA A receptor-mediated inhibition, and in GABA A receptor modulation by benzodiazepines, neurosteroids, and zinc, begin soon after SE and continue as animals become epileptic. [7] [8] [9] [10] Several laboratories have documented changes in GABA A receptor subunit composition in human temporal lobe epilepsy (TLE) and in animal models of TLE. 7, 9, 11, 12 In the pilocarpine model of SE in adult rodents, GABA A receptor ␣1-subunit mRNA expression decreases, ␣4-subunit mRNA expression increases in dentate granule cells (DGCs) of the hippocampus, and animals uniformly go on to develop the recurrent spontaneous seizures that define epilepsy. 7 The change in subunit expression correlates with a decreased sensitivity to zolpidem augmentation and increased sensitivity to zinc inhibition of GABA A receptor responses. 7 Similar functional and subunit expression changes have been observed in DGCs isolated from surgically resected hippocampus from patients with intractable TLE. 12 The changes in GABA A receptor subunit expression and function in DGCs of epileptic animals precede the development of epilepsy, suggesting that these changes contribute to the epileptogenesis process. In contrast, neonatal SE (postnatal day 10) in rats results in increased GABA A receptor ␣1-subunit expression and does not subsequently lead to development of epilepsy. 13 These studies suggest that GABA A receptor subunit alterations may be an important component of epileptogenesis. To more directly determine if GABA A receptor changes are critical contributors to epilepsy development, we used gene transfer to prevent these GABA A receptor subunit changes. To directly test the hypothesis that the expression of higher ␣1-subunit levels inhibits development of epilepsy after SE, an adeno-associated virus (AAV) gene transfer vector (AAV2), serotype 5, was designed to express a bicistronic RNA that codes for both the GABA A receptor ␣1-subunit and the reporter (enhanced yellow fluorescence protein [eYFP]).
14 Expression of this RNA was placed under control of the GABA A receptor ␣4-subunit gene (GABRA4) core promoter region, because this was previously shown to be markedly activated in dentate gyrus (DG) after SE 15 : activity of the ␣4 promoter is upregulated after SE, resulting in enhanced ␣1 expression in DG.
The AAV vector containing either the ␣1/eYFP fused cDNA (AAV-␣1) or the eYFP reporter only (AAVeYFP) was injected into the DG of adult rats, and SE was induced 2 weeks later by intraperitoneal injection of pilocarpine (385 mg/kg).
14 Rats injected with AAV-␣1 showed threefold higher levels of ␣1-subunits in the DG by 2 weeks after SE compared to the control groups. Rats were continuously video-EEG monitored to determine the latency for development of spontaneous seizures. AAV-␣1 injection resulted in a threefold increase in the mean time to the first spontaneous seizure after SE, and only 39% of AAV-␣1 injected rats were observed to develop spontaneous seizures in the first 4 weeks after SE, compared with 100% of rats receiving sham injections. Because all groups of rats experienced similar SE after pilocarpine injection, these findings provide the first direct evidence that increasing the levels of a single GABA A receptor subunit in the DG can inhibit the development of spontaneous seizures after SE. Together, these data support a role for GABA A receptor ␣-subunit changes in the process of epileptogenesis.
MECHANISMS REGULATING GABA A RECEPTOR SUBUNIT EXPRESSION

␣1 Subunit regulation
Although viral gene transfer is a promising therapeutic avenue for modifying aberrant gene expression associated with epileptogenesis, producing the optimal level of expression over a prolonged period can be challenging. Another possible approach is to modify the mechanisms regulating gene expression. Recent work in our laboratories has established cAMP response element binding protein (CREB) and inducible cAMP early repressor (ICER) as critical mediators of the GABA A receptor ␣1-subunit mRNA decreases that occur after SE in the DG. The CREB is a stimulus-induced bZIP transcription factor that is activated by phosphorylation at its Ser 133 site. Phosphorylated CREB (pCREB) dimerizes and binds to cAMP response element (CRE) motifs on promoters that contain the consensus sequence TGACGTCA. 16 Along with its chromatin regulator, the CREB binding protein (CBP), pCREB upregulates transcription of target genes.
Transcriptional regulation through CREB has been implicated in mechanisms of cell survival, plasticity, and learning and memory paradigms. 17 Target genes of pCREB include CREB family members encoding cAMP response element modulator (CREM), ICER, and activating transcription factors. These para-and homologs of CREB also bind CRE elements to modulate the transcription of particular genes. The CREM gene produces many spliced isoforms that can act as transcriptional repressors or activators. One of these repressor forms is ICER, a group of four proteins made from an internal promoter in the CREM gene. 18 ICER can act as a homodimer at the CRE site or heterodimerize with CREB to directly block CREB-induced transcription.
The human ␣1 promoter contains a functional CRE, 19 making CREB and its family members potential regulators of ␣1 gene expression in epilepsy. Several studies using adult animal models of epilepsy suggest that seizures upregulate pCREB or CREM and ICER activity. 20, 21 Our laboratory has found sustained increases in both pCREB and ICER in the DG of the hippocampus, continuing 1-48 hours after pilocarpine-induced SE. 22 Using chromatin immunoprecipitation and DNA pulldown studies, increased pCREB and ICER binding at the CRE site of GABA A receptor ␣1-subunit gene (GABRA1) were also observed after SE. 22 Further, in transfected primary hippocampal neurons manipulating CREB and ICER levels showed that overexpression of CREB and ICER together decreases GABRA1 promoter and reporter activity and overexpression of ICER alone decreases the levels of endogenous ␣1-subunits at the cell surface. 23 These findings suggest that CREB and ICER are important regulators of seizure-induced GABRA1 changes.
The excessive neuronal activity associated with SE stimulates many different signaling pathways that could result in enhanced phosphorylation of CREB and expression of ICER. 24 Determining which of these pathways mediates the increase in ICER expression critical for decreased transcription of the GABA A receptor ␣1-subunit is crucial to understanding how crosstalk between different signaling pathways can lead to specific changes in inhibitory neurotransmission. The focus of our studies was on brain derived neurotrophic factor (BDNF) as a potential regulator of ICER, because BDNF expression increases markedly after SE [25] [26] [27] [28] [29] and because BDNF differentially regulates the abundance of both ␣1-and ␣4-subunits in cultured neurons. 29 Results demonstrated that BDNF treatment of primary hippocampal neurons in culture produces similar changes in ␣-subunit levels as observed after SE: 24 hours after BDNF treatment, ␣1 levels decreased 42% and ␣4 levels increased 120%. 29 How does BDNF regulate ␣1-subunit levels? Surprisingly, it relies on activation of the Janus kinase-signal transducer and activators of transcription (JAK-STAT) pathway that in turn controls the synthesis of ICER, a repressor of GABRA1 transcription. The JAK-STAT pathway is activated by cytokines binding to their specific receptors, resulting in transphosphorylation of JAK kinases, which then leads to phosphorylation of STAT proteins. 30 -34 Phosphorylation of STAT proteins on tyrosine residues leads to STAT homo-or heterodimerization, translocation from the cytoplasm to the nucleus, and binding to specific DNA elements (STAT recognition sites) to regulate target gene expression. 31, 32, 35 Such an element is found in the ICER promoter, and we have shown that pSTAT3 association with this site is enhanced after SE in the DG. 22 Furthermore, siRNA knockdown of STAT3 inhibits BDNF-induced ICER, as does blockade of the JAK-STAT signaling pathway with pyridone 6 in primary hippocampal cultures. Most importantly, pyridone 6 administration in vivo into the DG prior to SE blocks both ICER induction and decreased transcription of GABRA1. 22 These findings suggest that the interplay of the CREB, JAK-STAT, and BDNF signaling pathways are critical for the decrease in ␣1-subunit levels that occurs in response to SE and that these pathways may provide novel therapeutic targets for epilepsy. In fact, several drugs that specifically inhibit the activity of JAK2 36, 37 or block downstream STAT activation 38, 39 have already been identified as potential agents in cancer chemotherapy and are in clinical trials. We are currently testing these agents in primary neuronal cultures to determine whether they may also provide alternative therapy for the future treatment of epilepsy. The relationship of cancer biology to neurobiology has not yet been described, and it will be of value to learn how postmitotic cells of the nervous system use the molecules characteristic of proliferation to modulate their responses to injury.
␣4 Subunit regulation
The GABA A receptors that contain ␣4-subunits have unique pharmacologic properties, such as insensitivity to benzodiazepines and increased sensitivity to zinc blockade. 40 Receptors containing ␣4-subunits are most often found with the ␦-subunit, rather than the ␥-subunit, in combination with ␣␤. These ␣4␤␦ GABA A receptors are localized to extrasynaptic sites and contribute to tonic inhibition. A minor population of ␣4␤␥2 GABA A receptors are found within DG synapses, where they are proposed to affect both the rise time and decay of synaptic currents. 41 In addition to the decrease in ␣1-subunit expression, there is a marked increase in ␣4-subunit expression during epileptogenesis in TLE models, which in an increase in the abundance of ␣4␥2-containing receptors and a reduction in ␣1␥2-containing receptors. 22 The change in receptor subtype from ␣1␤␥2 to ␣4␤␥2 may contribute to epileptogenesis, in that ␣4-containing GABA A receptors have been shown to desensitize rapidly, especially when assembled with ␤3-subunits. 42 In addition, GABA A receptors containing the ␣4-subunit are very sensitive to zinc blockade, 40 as is seen in DGCs of epileptic brain. 7 Our studies have shown that the alteration in ␣4 levels is transcriptionally mediated via an increase in the expression of the transcription factor early growth response factor 3 (Egr3). 15 The Egr family consists of four proteins (Egr1, -2, -3, and -4) that share nearly identical zinc finger DNA binding domains and bind to a common Egr response element consensus sequence: GCG T/GGG GCG. 43 Work in our laboratories has demonstrated induction of Egr family transcription factors after SE, with increases in protein levels of Egr3 and enhanced binding of Egr3 to the GABRA4 promoter in the DG of the hippocampus 24 hours after pilocarpine-induced SE. 15 Similar to its critical role in decreased expression of ␣1-containing GABA A receptors, BDNF again is the endogenous signal that induces Egr3 synthesis and over-expression of ␣4 GABA A receptors-in this case, however, through different signaling pathways: protein kinase C and mitogen activated protein kinase (PKC-MAPK). 29 Such findings establish the role of BDNF as a multifunctional stimulator of altered inhibition in the hyperactivated nervous system. (For a schematic presentation, see FIG. 1.) 
ALTERATION OF OTHER EPILEPTOGENESIS GENES
The approach we describe of identifying changes in gene expression during epileptogenesis in critical brain regions, and then examining the functional effect of preventing or augmenting these changes, has been applied to a number of genes.
Galanin is a bioactive compound that coexists with classical neurotransmitters and often inhibits their release. Galanin mediates its action via three types of G protein-linked receptors, GaR1-3. It is abundant in several brain structures, including the hippocampus, where its action is predominantly inhibitory. 44 In animal models of SE, there is an acute reduction in the levels of galanin in hippocampus. 44 Galanin injection before induction of SE shortens the duration of SE, 44 whereas, galanin knock-out mice have an increased propensity to S T A T 3 develop SE. 45 Using a gene therapy approach, Haberman et al. 46 showed that injection of AAV containing coding sequence for active galanin peptide into inferior collicular cortex increased the threshold for seizure generation to electrical stimulation. A recent study by KanterSchlifke et al. 47 showed that overexpression of galanin by injection of AAV containing a galanin gene in hippocampus decreased duration of afterdischarges and increased the latency to develop generalized seizures in the kindling model of epilepsy. A more direct approach to increasing the activity of galanin is to use galanin receptor agonists that can cross the blood-brain barrier. Galnon, a low molecular weight (677 Da) galanin receptor ligand, has been shown to affect various physiological as well as pathological functions. 48 Galnon has been shown to have anticonvulsant activity in the pentylenetetrazolinduced seizure model: galnon injection reduced the seizure score and increased the seizure latency. 49 Neuropeptide Y (NPY) has been associated with a number of biologically important functions, such as learning and memory. Neuropeptide Y mediates its action through six receptors (Y1-6) that belong to the G-protein coupled superfamily. In a number of studies conducted in different animal models of epilepsy, an increase in NPY expression in the mossy fiber pathway of the hippocampus was observed, suggesting a modulatory role of NPY in epileptic activity. 50 Furthermore, mice that lack NPY have a reduced threshold for developing seizures with pentylenetetrazol and also develop spontaneous seizures. 51 A recent study by Noé et al. 52 showed that AAV containing an NYP gene injected in rats 14 weeks after SE induction halted the progression of seizure activity. Adenosine is an inhibitory modulator that mediates it action through four G-protein coupled receptors: A 1 , A 2A , A 2B , and A 3 . Decreased adenosine levels 53 and long-term reduction in A 1 receptors 54 have been observed in different animal models of epileptogenesis. Adenosine antagonists have been shown to reduce the threshold for seizure development. 53 In the hippocampal kindling model of epilepsy, implantation in rats with myoblast grafts engineered to release adenosine by inhibiting adenosine kinase (an enzyme that converts adenosine to adenosine 3=,5=-monophosphate) reduced seizure duration for 3 weeks after transplantation. 55 Similarly, implantation of human mesenchymal stem cells transduced with lentivirus containing RNAi against adenosine kinase in the hippocampus of mice resulted in a 35% reduction in seizure duration after kainic acid injection, compared with control mice that were implanted with scrambled control sequence. 56 In another recent study, Wilz et al. 57 showed that adenosine released from implants over a period of 14 days inhibited development of epilepsy in the kindling model. These studies provide a strong rationale for use of adenosine augmentation as a therapy for intractable epilepsy.
BDNF
Glial cell line-derived neurotrophic factor (GDNF), a member of the GDNF family of ligands, 58 has been shown to increase after seizures, 59 and intraventricular infusion of GDNF has been shown to suppress seizures in various animal models of epilepsy. 60, 61 A recent study by Kanter-Schlifke et al. 62 showed that overexpression of GDNF using recombinant adeno-associated viral (rAAV) vector suppressed generalized seizure activity but could not prevent kindling epileptogenesis.
CONCLUSION
The full range of gene expression changes that are involved in epileptogenesis and the molecular mechanisms that underlie them are just beginning to be characterized. Studies in animal models suggest that modulation of the expression of a number of these genes via viral-mediated overexpression or manipulation of their upstream regulation may be useful therapeutic tools for the future treatment of epilepsy.
The transcription factors discussed in this review likely compose only a part of the cascade of signaling events that are initiated by seizures, but it is clear that the BDNF, JAK-STAT, CREB-ICER, and Egr3 signaling pathways play important roles. Recent work characterizing their functions in GABA A receptor ␣1-and ␣4-subunit changes in the DG after SE provides important leads for future development of molecular therapies aimed at restoring the balance of excitation and inhibition in the nervous system. Nonetheless, the upstream components of these pathways, and the exact means through which they confer vulnerability to epilepsy, must be further elucidated. Furthermore, because these pathways regulate a myriad of genes with diverse functions, modulation of any of these pathways may have a multitude of downstream effects, many of which may involve cell-and region-specific responses throughout the brain. Therefore, the final effects of pathway blockade on epileptogenesis may be difficult to predict.
For example, although the enhanced GABA A receptor ␣1-subunit expression in the DG that results from JAK-STAT pathway blockade and subsequent ICER inhibition would be expected to have an antiepileptic effect, mutant mice lacking ICER have accelerated kindling 63 and develop more severe epilepsy after pilocarpine-induced SE. 64 Consistent with this finding, ICER-overexpressing mice show retardation of kindling development. 63 Whether the effects of acute and transient blockade of ICER upregulation at the time of SE specifically in the hippocampal formation will have a similar effect on epileptogenesis as constitutive under-or overexpression of ICER globally in the brain remains to be determined. Finally, as several of these signaling path-ways have been implicated in the regulation of learning, memory and cell survival, the effects of modulation of these pathways on these critical parameters will need to be closely monitored.
Promising data from animal models also support the potential antiepileptic, and possibly antiepileptogenic, effects of altering the expression of several other neuromodulatory compounds, including galanin, neuropeptide Y, and adenosine. Just as with transcription factor modulation, however, there is still much work to be done to determine the methods for optimal treatment, such as when to initiate delivery and how long to treat. Equally important is how much modulation is necessary for treatment efficacy. Given the adaptive nature of the brain to overcome multiple insults, it would not be surprising if we find that small changes in gene expression using these approaches will have marked effects on restoring brain function. However, we are really at the starting gate, because we know little about the long-term effects of such viral delivery on learning, memory, and cell survival. Because all of the signal transduction pathways and neuromodulatory compounds discussed in this review have highly complex effects, affecting a great many receptors and their effector systems, this area of inquiry is particularly promising for new drug delivery targets and novel drug discovery in epilepsy.
